Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
- 1 October 1998
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 352 (9138), 1426-1432
- https://doi.org/10.1016/s0140-6736(98)07124-4
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Epidemiology of hepatitis CHepatology, 1997
- Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled studyJournal of Hepatology, 1996
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and durationHepatology, 1996
- An algorithm for the grading of activity in chronic hepatitis CHepatology, 1996
- Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: Results of the first multicentre Australian trialJournal of Hepatology, 1995
- Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirinJournal of Gastroenterology and Hepatology, 1994
- Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assayJournal of General Virology, 1993
- A pilot study of ribavirin therapy for chronic hepatitis CHepatology, 1992
- Long-term follow-up of patients with chronic hepatitis C treated with α-interferonHepatology, 1992
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1981